Type 1 Diabetes Market Outlook

Thelansis’s “Type 1 Diabetes Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Type 1 Diabetes treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Type 1 Diabetes Overview

Type 1 diabetes (T1D) is a chronic, immune-mediated disease driven by the progressive destruction of insulin-producing pancreatic beta-cells, culminating in absolute insulin deficiency and lifelong dependence on exogenous insulin. Historically, diagnosis was strictly reactive, occurring only after extensive beta-cell loss manifested as severe clinical catabolism (polyuria, polydipsia, weight loss, and marked hyperglycemia or diabetic ketoacidosis). However, the modern clinical paradigm has undergone a profound shift toward early detection, formally categorizing T1D into three distinct stages based on the presence of islet autoantibodies and dysglycemia. This staging framework has paved the way for revolutionary disease-modifying therapies—most notably teplizumab, an anti-CD3 monoclonal antibody utilized to delay the onset of Stage 3 clinical disease in high-risk individuals. Because the management of T1D is a highly dynamic process, the standard of care has aggressively evolved beyond traditional manual injections; it now universally prioritizes the early initiation of continuous glucose monitoring (CGM) systems and automated insulin delivery (AID) closed-loop technologies to maximize glycemic time-in-range and minimize severe hypoglycemia. Furthermore, longitudinal care must be highly individualized, requiring iteratively adapted psychosocial support alongside rigorous screening for microvascular and macrovascular complications—such as cardiovascular disease, neuropathy, and nephropathy—to ensure comprehensive cardiometabolic protection across the patient’s lifespan.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)